Key Takeaways
- • IGIS Asia Investment Management and South Korean bio-pharma group CHA Bio have formed a strategic partnership to develop and invest in life-science real estate assets across the Asia-Pacific region, targeting R&D facilities, manufacturing plants, hospitals, and medical office complexes.
- • The venture will establish the Korea Life Science Investment Platform (KLSIP) as its primary vehicle, with dedicated capital allocation for facility development concentrated in South Korean metropolitan markets.
- • The partnership addresses structural realignment in APAC's life sciences sector, which represented only 1% ($717 million USD) of total real estate investment in 2022, signaling significant growth potential in an underpenetrated market segment.
- • The platform's scope extends beyond South Korea to broader Asia-Pacific markets, positioning the partners to capitalize on expanding demand for specialized life-science real estate infrastructure across the region.
Summary
IGIS Asia Investment Management has partnered with CHA Bio, a South Korean bio-pharma conglomerate, to establish a dedicated life-science real estate investment platform serving the Asia-Pacific region. The venture will focus on developing and acquiring specialized facilities including research and development centers, pharmaceutical manufacturing complexes, hospitals, and medical office spaces.
The partnership will operate through the Korea Life Science Investment Platform (KLSIP), which IGIS has committed to capitalize with dedicated investment capital. The platform will prioritize deployment of capital in South Korean metropolitan areas while maintaining optionality for expansion across broader Asia-Pacific markets. This structure allows the partners to combine IGIS's real estate investment expertise with CHA Bio's established presence and technical knowledge within Korea's bio-pharma ecosystem.
The timing of this venture reflects a significant market opportunity. Life sciences real estate investment in Asia-Pacific remains substantially underpenetrated, comprising only 1% of total regional real estate investment as of 2022 ($717 million USD). Industry participants characterize the APAC life sciences sector as undergoing structural realignment, requiring fundamental strategic repositioning to capture growth in R&D, manufacturing, and supporting healthcare infrastructure. The KLSIP venture positions both parties to address this gap while establishing first-mover advantages in a high-growth segment within one of the world's most dynamic bio-pharma markets.
The partnership will operate through the Korea Life Science Investment Platform (KLSIP), which IGIS has committed to capitalize with dedicated investment capital. The platform will prioritize deployment of capital in South Korean metropolitan areas while maintaining optionality for expansion across broader Asia-Pacific markets. This structure allows the partners to combine IGIS's real estate investment expertise with CHA Bio's established presence and technical knowledge within Korea's bio-pharma ecosystem.
The timing of this venture reflects a significant market opportunity. Life sciences real estate investment in Asia-Pacific remains substantially underpenetrated, comprising only 1% of total regional real estate investment as of 2022 ($717 million USD). Industry participants characterize the APAC life sciences sector as undergoing structural realignment, requiring fundamental strategic repositioning to capture growth in R&D, manufacturing, and supporting healthcare infrastructure. The KLSIP venture positions both parties to address this gap while establishing first-mover advantages in a high-growth segment within one of the world's most dynamic bio-pharma markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.